Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
Taking both medications together can put you at an increased risk for certain serious conditions like serotonin syndrome
These facilities are restricted from producing copies of the drugs when the shortage is resolved, though the FDA allows a grace period to fulfill existing in-house orders
Frequently Asked Questions (FAQs) References: Janumet 50 mg/1000 mg film-coated tablets- Summary of Product Characteristics (SmPC) - (emc) [Internet]
US$ 29.82
US$ 28.60
US$ 28.20
US$ 24.74
US$ 22.33
US$ 21.91
